For patients diagnosed with rare diseases like hemophilia and muscular dystrophy, treatment has historically been difficult and the prognoses terminal. But the advent of new cell and gene therapies are providing hope, as they fight the root cause of disease and provide patients with life-altering, and in some cases, life-saving treatments.

Listen to this episode of the Business Group on Health podcast to hear from Sarah Emond, ICER’s President-Elect, about the complexities of cell and gene therapies including how they differ from traditional treatments, challenges like access and manufacturing, and promising payment mechanisms to finance these high-cost therapies.

Guest: Sarah Emond, President-Elect, Institute for Clinical and Economic Review (ICER)

Tags: Business Group on Health, cell and gene therapies, cell therapy, drugs, gene therapy, hemophilia, muscular dystrophy, pharmaceuticals, Sarah Emond
 
Posted in: Audio Podcast, Business Group on Health, Healthcare